Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer

J. Kubes, J. Cvek, V. Vondracek, M. Pala, D. Feltl,

. 2011 ; 187 (10) : 651-5. [pub] 20110923

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc12028041
E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2006-08-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 21947124
DOI 10.1007/s00066-011-2246-2
Knihovny.cz E-zdroje

BACKGROUND AND PURPOSE: To present the feasibility and results of accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) in the treatment of locally advanced head and neck cancer. PATIENTS AND METHODS: A total of 65 patients were treated between June 2006 and August 2009. The distribution of clinical stages was as follows: II 11%, III 23%, IV 61%, and not defined 5%. RESULTS: The median follow-up was 30.5 months. The treatment plan was completed in 94% of patients. Patients were treated using the conformal or intensity-modulated radiotherapy (IMRT) technique. The median overall treatment time was 37 days (13-45 days). The mean radiotherapy dose was 68.4 Gy (16-74 Gy). Overall survival was 69% after 2 years. Disease-free survival was 62% after 2 years. Acute toxicity ≥ grade 3(RTOG scale) included mucositis (grade 3: 42.6%), pharynx (grade 3: 42.3%), skin (grade 3: 9.5%), larynx (grade 3: 4%), while late toxicity affected skin (grade 3: 6.25%) and salivary glands (grade 3: 3.7%). CONCLUSION: Accelerated radiotherapy with concomitant boost technique is feasible in patients with locally advanced head and neck cancer, has an acceptable toxicity profile, and yields promising treatment results.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12028041
003      
CZ-PrNML
005      
20121210111253.0
007      
ta
008      
120817e20110923gw f 000 0#eng||
009      
AR
024    7_
$a 10.1007/s00066-011-2246-2 $2 doi
035    __
$a (PubMed)21947124
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kubes, Jiri $u Institute of Radiation Oncology, Prague, The Czech Republic. jiri.kubes@fnb.cz
245    10
$a Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer / $c J. Kubes, J. Cvek, V. Vondracek, M. Pala, D. Feltl,
520    9_
$a BACKGROUND AND PURPOSE: To present the feasibility and results of accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) in the treatment of locally advanced head and neck cancer. PATIENTS AND METHODS: A total of 65 patients were treated between June 2006 and August 2009. The distribution of clinical stages was as follows: II 11%, III 23%, IV 61%, and not defined 5%. RESULTS: The median follow-up was 30.5 months. The treatment plan was completed in 94% of patients. Patients were treated using the conformal or intensity-modulated radiotherapy (IMRT) technique. The median overall treatment time was 37 days (13-45 days). The mean radiotherapy dose was 68.4 Gy (16-74 Gy). Overall survival was 69% after 2 years. Disease-free survival was 62% after 2 years. Acute toxicity ≥ grade 3(RTOG scale) included mucositis (grade 3: 42.6%), pharynx (grade 3: 42.3%), skin (grade 3: 9.5%), larynx (grade 3: 4%), while late toxicity affected skin (grade 3: 6.25%) and salivary glands (grade 3: 3.7%). CONCLUSION: Accelerated radiotherapy with concomitant boost technique is feasible in patients with locally advanced head and neck cancer, has an acceptable toxicity profile, and yields promising treatment results.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a studie proveditelnosti $7 D005240
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a nádory hypofaryngu $x mortalita $x patologie $x radioterapie $7 D007012
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory úst $x mortalita $x patologie $x radioterapie $7 D009062
650    _2
$a nádory nosohltanu $x mortalita $x patologie $x radioterapie $7 D009303
650    _2
$a staging nádorů $7 D009367
650    _2
$a otorinolaryngologické nádory $x mortalita $x patologie $x radioterapie $7 D010039
650    _2
$a radiační poranění $x etiologie $7 D011832
650    _2
$a konformní radioterapie $x metody $7 D020266
650    _2
$a radioterapie s modulovanou intenzitou $x metody $7 D050397
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cvek, Jakub
700    1_
$a Vondracek, Vladimir
700    1_
$a Pala, Miloslav
700    1_
$a Feltl, David
773    0_
$w MED00010658 $t Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] $x 1439-099X $g Roč. 187, č. 10 (20110923), s. 651-5
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21947124 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121210111330 $b ABA008
999    __
$a ok $b bmc $g 950083 $s 785387
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 187 $c 10 $d 651-5 $e 20110923 $i 1439-099X $m Strahlentherapie und Onkologie $n Strahlenther Onkol $x MED00010658
LZP    __
$a Pubmed-20120817/11/04

Najít záznam

Citační ukazatele

Možnosti archivace